The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Niagen Bioscience director Yu Wing Tak Wendy received a grant of stock options covering 31,746 shares of Common Stock. The options have an exercise price of $3.45 per share, vest 100% on June 24, 2027, and expire on June 23, 2036. Following this compensation grant, she holds 31,746 stock options directly.
Niagen Bioscience, Inc. director Ng Wang Yu Gary reported a compensation-related stock option grant. He received an option to acquire 31,746 shares of common stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036. Following this grant, he holds options for 31,746 underlying shares directly.
Niagen Bioscience, Inc. director Ann Cohen received a grant of stock options covering 31,746 shares of common stock. The options have an exercise price of $3.45 per share and expire on June 23, 2036. They vest 100% on June 24, 2027, and following this award she holds 31,746 options directly.
Niagen Bioscience, Inc. director Patrick Kristin received a grant of stock options representing the right to buy 31,746 shares of common stock. The options have an exercise price of $3.4500 per share and vest 100% on June 24, 2027. After this grant, he holds 31,746 derivative securities linked to common stock, and the options expire on June 23, 2036.
Niagen Bioscience director Hamed Shahbazi received a new stock option grant. The award covers 31,746 shares of Common Stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036, with no shares sold in this filing.
Niagen Bioscience director Steven D. Rubin received a compensation-related grant of stock options. He was awarded 31,746 options to buy Common Stock at an exercise price of $3.45 per share. The options vest 100% on June 24, 2027 and expire on June 23, 2036. After this grant, he holds 31,746 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Niagen Bioscience director Frank L. Jaksch Jr. received a compensation-related stock option grant. He was awarded options to acquire 31,746 shares of Common Stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036. Following this grant, he holds 31,746 derivative securities directly, with no open-market buying or selling reported in this filing.
Niagen Bioscience, Inc. reported first-quarter 2026 net sales of $31.5 million, up 3% year-over-year, with Tru Niagen® contributing $22.4 million. Gross margin was 63.5%, reflecting a favorable business mix.
Net income was $6.3 million, helped by a $4.8 million gain on the divestiture of the Analytical Reference Standards and Services operating segment, while adjusted EBITDA was $3.8 million. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Cash and cash equivalents totaled $66.5 million with no outstanding borrowings, after using $1.2 million in operating cash flow and repurchasing $2.4 million of common stock.
The company reaffirmed its 2026 outlook for net sales to increase 10–15% year-over-year, excluding the divested segment, and expects slightly higher gross margin. It plans higher sales and marketing and research and development spending, while general and administrative expense is now projected to rise by $3–$4 million.
Niagen Bioscience, Inc. reported higher profitability for the three months ended March 31, 2026, driven by its core Niagen® businesses and a divestiture gain. Net sales rose to $31.5 million from $30.5 million, led by growth in Tru Niagen® consumer products and food-grade Niagen® ingredient sales.
Net income increased to $6.3 million from $5.1 million, helped by a $4.8 million gain on the sale of the analytical reference standards and services segment. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Gross margin remained stable at about 63% as stronger e‑commerce mix offset shifts in ingredient margins.
Operating cash flow swung to a $1.2 million use of cash, mainly due to higher receivables and inventory to support demand. The company ended the quarter with $66.5 million in cash and cash equivalents and repurchased about 490,000 shares for $2.4 million. Management expects existing cash and operating cash flows to cover obligations for at least the next twelve months.